|
|
||||||||
Department of Medicine and The Sam and Rose Stein Institute for Research on Aging, University of California at San Diego, La Jolla, CA 92093.
High-affinity pathologic rheumatoid factor (RF) B cells occur in autoimmune diseases such as rheumatoid arthritis, but are deleted in healthy individuals. The reasons for the survival and differentiation of these autoreactive B cells in rheumatoid arthritis are not known. Previous studies in mice transgenic for a human IgM RF have shown that peripheral encounter with soluble human IgG leads to deletion of high-affinity RF B cells; however, deletion can be prevented when concomitant T cell help is provided. This study aimed to further discern the minimal factors necessary not only for the in vivo survival of RF B cells, but also for their differentiation into Ab-secreting cells. The combination of MHC class II-reactive T cells and Ag induced the production of RF in human IgM RF transgenic mice, while either stimulus alone was ineffective. Neutralizing Abs against CD40 ligand (CD40L), but not against IL-4 or IL-15, abrogated IgM-RF production. Moreover, blockade of CD40L-CD40 allowed IgG to delete the RF precursor cells. Most importantly, activating Abs to CD40 could substitute entirely for T cell help in promoting the survival of RF precursors and in stimulating RF synthesis in T cell deficient animals. The data indicate that CD40 signaling alone can prevent deletion of RF B cells by Ag and in the presence of IgG is sufficient to trigger RF synthesis. The results suggest that selective induction of apoptosis in high-affinity RF B cells may be achieved by blockade of CD40L-CD40 interaction.
This article has been cited by other articles:
![]() |
T. Hayashi, C. S. Gray, M. Chan, R. I. Tawatao, L. Ronacher, M. A. McGargill, S. K. Datta, D. A. Carson, and M. Corr Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7 PNAS, February 24, 2009; 106(8): 2764 - 2769. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Munroe and G. A. Bishop A Costimulatory Function for T Cell CD40 J. Immunol., January 15, 2007; 178(2): 671 - 682. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. W. Edwards and G. Cambridge Prospects for B-cell-targeted therapy in autoimmune disease Rheumatology, February 1, 2005; 44(2): 151 - 156. [Full Text] [PDF] |
||||
![]() |
D. Daoussis, A. P. Andonopoulos, and S.-N. C. Liossis Targeting CD40L: a Promising Therapeutic Approach Clin. Vaccine Immunol., July 1, 2004; 11(4): 635 - 641. [Full Text] |
||||
![]() |
J. C. W. Edwards and G. Cambridge Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology, February 1, 2001; 40(2): 205 - 211. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |